Metabolic Solutions Inc.   Report issue

For profit Phase 2
Founded: Nashua NH United States (1990)

Organization Overview

First Clinical Trial
2005
NCT00628732
First Marketed Drug
1999
urea-13c (PyloPlus)
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Alternative names

METABOLIC SOLUTIONS | Metabolic Solutions Development Company | MSDC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Gastroparesis (Phase 2)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 7